Susquehanna International Group’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Susquehanna International Group’s Portfolio TCON Stock Details TCON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-770	Closed	-$31K	–	14358
2022 Q2	$31K	Sell	770 -1,125	-59%	-$43.5K	﹤0.01%	12210
2022 Q1	$100K	Sell	1,895 -675	-26%	-$33.9K	﹤0.01%	11917
2021 Q4	$142K	Buy	2,570 +175	+7%	+$11.2K	﹤0.01%	11858
2021 Q3	$185K	Buy	2,395 +1,410	+143%	+$119K	﹤0.01%	11581
2021 Q2	$128K	Buy	985 +95	+11%	+$13.1K	﹤0.01%	11948
2021 Q1	$146K	Buy	+890	New	+$171K	﹤0.01%	11675

Other funds holding TCON

GPFA

Game Plan Financial Advisors Westlake, Ohio $269M AUM 28.74% 1-Year Est. Return

Susquehanna International Group's TCON Position: Q2 2024 in Review

Susquehanna International Group sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q2 2024, closing a stake of 3,893 shares — an estimated $33.5K sold.

Susquehanna International Group first reported a position in TCON in Q1 2015 and held it in 12 quarters. The position peaked at $173K in Q1 2015. 1 fund tracked by Wall St. Rank holds TCON as of Q2 2024.

Susquehanna International Group reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Susquehanna International Group sold 3,893 TRACON Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $33.5K.
Susquehanna International Group first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q1 2015 and held it in 12 quarters.
Susquehanna International Group's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $173K in Q1 2015.
1 fund tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on Susquehanna International Group's 13F filing for Q2 2024, filed 15 Aug 2024.